US2010255579A1PendingUtilityA1
Tumor antigen protein and use thereof
Assignee: DAINIPPON SUMITOMO PHARMA COPriority: Sep 27, 2002Filed: Feb 8, 2010Published: Oct 7, 2010
Est. expirySep 27, 2022(expired)· nominal 20-yr term from priority
Inventors:Noriyuki SatoTomohide TsukaharaYuki NabetaSatoshi KawaguchiHideyuki IkedaTakuro WadaToshihiko Yamashita
A61P 35/00C07K 14/4748A61K 38/1709A61P 37/04A61K 39/00
37
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
An inducer of cytotoxic T cells comprising as an active ingredient a protein which comprises the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2, or a peptide derived from the protein above is provided.
Claims
exact text as granted — not AI-modified1 . An inducer of cytotoxic T cell (CTL) comprising as an active ingredient a protein which comprises the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2.
2 . An inducer of CTL comprising a polynucleotide encoding a protein comprising the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2.
3 . The inducer of CTL of claim 2 , wherein the polynucleotide is a polynucleotide comprising a base sequence shown in SEQ ID NO: 1, position 337-1878 of SEQ ID NO: 1 or SEQ ID NO: 3.
4 . A method for producing an antigen-presenting cell comprising the step of bringing a cell having antigen-presenting ability into contact with (a) or (b) in vitro:
(a) a protein comprising the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2; (b) a nucleic acid comprising a polynucleotide encoding the protein of (a).
5 . A method for inducing a CTL comprising the step of bringing peripheral lymphocyte cells into contact with (a) or (b) in vitro:
(a) a protein comprising the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2; (b) a nucleic acid comprising a polynucleotide encoding the protein of (a).Join the waitlist — get patent alerts
Track US2010255579A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.